News

Clinical Capsules


 

Of 1,299 subjects evaluated in the latest follow-up exam, 210 had developed nuclear cataracts since the previous follow-up. The incidence of cataracts was significantly lower in subjects who took statins than in those who didn't (12% vs. 17%), the researchers said (JAMA 2006;295:2752–8).

Compared with those who didn't take statins, subjects who took simvastatin had an odds ratio of 0.28 for developing nuclear cataracts, those who took atorvastatin had an odds ratio of 0.73, and those who took all other statins had an odds ratio of 0.67.

Both the duration of statin use and the drug dosage may influence the protective effect against cataracts, but this study was not designed to assess either factor, the researchers noted.

Pages

Recommended Reading

Aggressive Secondary Prevention Urged in CHD
MDedge Internal Medicine
Whole Grain Barley Products Can Claim Heart Health Benefits
MDedge Internal Medicine
Imaging Targets Vulnerable Coronary Plaques
MDedge Internal Medicine
Sleep Apnea Treatment Noted as Cardioprotective
MDedge Internal Medicine
Hemofiltration Averts Contrast Nephropathy
MDedge Internal Medicine
High-Dose Statin Aids Renal Function in CHD
MDedge Internal Medicine
Ezetimibe/Simvastatin Outdoes Statin Alone for Lowering CRP
MDedge Internal Medicine
Ezetimibe/Simvastatin Combo Safe, Effective in Kidney Disease
MDedge Internal Medicine
Enoxaparin Beats Heparin as Adjunct in Acute MI
MDedge Internal Medicine
Bosentan Label Changes Address Hepatotoxicity
MDedge Internal Medicine